<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04675320</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A00036-33</org_study_id>
    <nct_id>NCT04675320</nct_id>
  </id_info>
  <brief_title>Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors</brief_title>
  <acronym>IMMUNOPARP</acronym>
  <official_title>Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Georges Francois Leclerc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Georges Francois Leclerc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study concerns the creation of a biological collection (blood samples) in patients with&#xD;
      Epithelial Ovarian Cancer in in order to describe the immune response with PARP inhibitors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim is to assess the impact of anti-PARP on peripheral immune populations and the amount&#xD;
      of DNA circulating; to correlate these data with tumor infiltration, with the initial&#xD;
      clinical characteristics and with the clinical course; compare the immunogenic effect of&#xD;
      different anti-PARPs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 7, 2020</start_date>
  <completion_date type="Anticipated">July 7, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 7, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>blood analysis</measure>
    <time_frame>up to 6 months</time_frame>
    <description>immunophenotyping,plasma library and PBMC bank.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Mutated BRCA epithelial ovarian cancer</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Recurrent epithelial ovarian cancer</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>Olaparib</description>
    <arm_group_label>Mutated BRCA epithelial ovarian cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>Niraparib or Olaparib</description>
    <arm_group_label>Recurrent epithelial ovarian cancer</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        cohorte 1 : patients with Mutated BRCA epithelial ovarian cancer - interviewed by Olaparib&#xD;
        cohorte 2 : patients with Recurrent epithelial ovarian cancer - maintained with Niraparib&#xD;
        or Olaparib&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Epithelial Ovarian Cancer&#xD;
&#xD;
          -  Eligible for treatment by anti-PARP treatment with Olaparib or Niraparib&#xD;
&#xD;
          -  informed consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non Epithelial Ovarian Cancer&#xD;
&#xD;
          -  Current or previous use of an immunosuppressive drug 14 days before inclusion&#xD;
&#xD;
          -  Pregnant or breastfeeding woman.&#xD;
&#xD;
          -  VIH et/ou VHB et/ou VHC positive&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-David FUMET</last_name>
    <phone>03 80 73 75 00</phone>
    <email>jdfumet@cgfl.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fernando BAZAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elsa KALBACHER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura MANSI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume MEYNARD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean David FUMET</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle DESOULIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvia ILIE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Audrey HENNEQUIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Courèche KADERBHAI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alice HERVIEU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leila BENGRINE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laure FAVIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 7, 2020</study_first_submitted>
  <study_first_submitted_qc>December 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PARP Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

